Show Summary Details
Page of

Treatment-Resistant Obsessive-Compulsive Disorder 

Treatment-Resistant Obsessive-Compulsive Disorder
Chapter:
Treatment-Resistant Obsessive-Compulsive Disorder
Author(s):

Robert Hudak

, Priya Gopalan

, and Darin D. Dougherty

DOI:
10.1093/med/9780199739981.003.0009
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2015. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy).

date: 25 November 2017

Obsessive-compulsive disorder (OCD) is the fourth most common psychiatric disorder, affecting approximately 2%–3% of the population. This chronic illness causes significant morbidity, and full remission of symptoms is relatively rare. Treatment resistance is commonly encountered when treating OCD as more than half of patients will not respond to standard treatments. A short review of the protocols for standard treatment of serotonin reuptake inhibitors combined with exposure and response prevention therapy is provided. A more extensive description follows of the steps that clinicians would employ in the case that the standard treatment proves to be insufficient. Strategies for changing medications and behavioral therapy in treatment-resistant patients are described. Augmentation with second-generation antipsychotic medications is reviewed as are the use of other augmenting agents. Because of the high rate of treatment resistance in OCD, a discussion of novel medications is provided, focusing on medications regulating glutamate, the most active area of OCD research at this time.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.